[A24-23] Nivolumab (melanoma, adjuvant, stage IIB or IIC) – Addendum to Project A23-94
Last updated 21.03.2024
Project no.:
A24-23
Commission:
Commission awarded on 06.03.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
DOI:
https://dx.doi.org/10.60584/A24-23_en
| Project no. | Title | Status |
|---|---|---|
| A23-94 | Nivolumab (melanoma, adjuvant, stage IIB or IIC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-03-21 A G-BA decision was published.